Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

被引:18
作者
Streetman, DS
Ellis, RE
Nafziger, AN
Leeder, JS
Gaedigk, A
Gotschall, R
Kearns, GL
Bertino, JS
机构
[1] Bassett Healthcare, Clin Pharmacol Res Ctr, Cooperstown, NY 13326 USA
[2] Bassett Healthcare, Dept Med, Cooperstown, NY 13326 USA
[3] Bassett Healthcare, Dept Pharm Serv, Cooperstown, NY 13326 USA
[4] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA
[5] Univ Missouri, Dept Pharmacol, Kansas City, MO 64110 USA
[6] Univ Missouri, Childrens Mercy Hosp & Clin, Div Pediat Clin Pharmacol & Expt Therapeut, Kansas City, MO 64110 USA
关键词
D O I
10.1016/S0009-9236(99)70018-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most dextromethorphan CYP2D6 phenotyping studies use a 30-mg dose, but data that show superiority of any particular dose are lacking. We compared metabolic ratios from six different dextromethorphan phenotyping doses to ascertain whether Linearity existed over a dosage range. Forty subjects were enrolled in the study. Each subject received 0.05 mg/kg, 0.15 mg/kg, 0.3 mg/kg, 30 mg, 0.8 mg/kg, and 1.2 mg/kg dextromethorphan in a randomized crossover fashion. Urinary dextromethorphan to dextrorphan molar ratios were used to measure CYP2D6 activity. Single blood samples were obtained for CYP2D6 genotyping, which revealed one poor metabolizer and 39 extensive metabolizers, A statistical difference was found for the molar ratio between the 0.8 mg/kg and the 1.2 mg/kg dose compared with the other four doses. None of the 39 genotypic extensive metabolizers were incorrectly phenotyped with any of these doses. These data support the use of moderate doses of dextromethorphan for phenotyping to avoid dose dependency.
引用
收藏
页码:535 / 541
页数:7
相关论文
共 23 条
[1]  
BOTSCH S, 1993, MOL PHARMACOL, V43, P120
[2]   RECENT DEVELOPMENTS IN HEPATIC DRUG OXIDATION - IMPLICATIONS FOR CLINICAL PHARMACOKINETICS [J].
BROSEN, K .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :220-239
[3]   1ST-PASS METABOLISM OF IMIPRAMINE AND DESIPRAMINE - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) :400-406
[4]   The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans [J].
Capon, DA ;
Bochner, F ;
Kerry, N ;
Mikus, G ;
Danz, C ;
Somogyi, AA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) :295-307
[5]   CLINICAL-PHARMACOLOGY OF PROPAFENONE [J].
CONNOLLY, SJ ;
KATES, RE ;
LEBSACK, CS ;
HARRISON, DC ;
WINKLE, RA .
CIRCULATION, 1983, 68 (03) :589-596
[6]   HIGH-DOSE DEXTROMETHORPHAN IN AMYOTROPHIC-LATERAL-SCLEROSIS - PHASE-I SAFETY AND PHARMACOKINETIC STUDIES [J].
HOLLANDER, D ;
PRADAS, J ;
KAPLAN, R ;
MCLEOD, HL ;
EVANS, WE ;
MUNSAT, TL .
ANNALS OF NEUROLOGY, 1994, 36 (06) :920-924
[7]   Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping [J].
Kashuba, ADM ;
Nafziger, AN ;
Kearns, GL ;
Leeder, JS ;
Shirey, CS ;
Gotschall, R ;
Gaedigk, A ;
Bertino, JS .
PHARMACOGENETICS, 1998, 8 (05) :403-410
[8]  
KUPFER A, 1986, XENOBIOTICA, V16, P421
[9]  
LAM YWF, 1993, THER DRUG MONIT, V15, P300
[10]   THE ROLE OF GENETICALLY-DETERMINED POLYMORPHIC DRUG-METABOLISM IN THE BETA-BLOCKADE PRODUCED BY PROPAFENONE [J].
LEE, JT ;
KROEMER, HK ;
SILBERSTEIN, DJ ;
FUNCKBRENTANO, C ;
LINEBERRY, MD ;
WOOD, AJJ ;
RODEN, DM ;
WOOSLEY, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (25) :1764-1768